"Platelet Aggregation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
| Descriptor ID |
D010974
|
| MeSH Number(s) |
G09.188.370.687 G09.188.390.600.640
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation".
This graph shows the total number of publications written about "Platelet Aggregation" by people in this website by year, and whether "Platelet Aggregation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Aggregation" by people in Profiles.
-
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24?months. Pediatr Blood Cancer. 2021 05; 68(5):e28977.
-
Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. Thromb Haemost. 2019 Jul; 119(7):1147-1153.
-
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).
-
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.
-
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):347-56.
-
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006 Mar; 151(3):689.e1-689.e10.
-
Thrombotic thrombocytopenic purpura-2005. Semin Thromb Hemost. 2005 Dec; 31(6):611-4.
-
Castration reduces platelet thromboxane A2 receptor density and aggregability. QJM. 2005 May; 98(5):349-56.
-
Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invasive Cardiol. 2003 May; 15(5):264-9.
-
Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003 Jan; 73(1):122-30.